SELL and COVID-19: However, when looking at the CD62L+ CD4+ T cell population, we found that recovered COVID-19 patients had greater frequencies of effector cells compared to non-severe patients (p<0.01), severe patients (p<0.01), and healthy controls (p<0.01).